3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Status
Completed
1
Sponsor Class
OTHER
1
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Head & Neck
1
Conditions
Carcinoma, Non-Small-Cell Lung
25
Colorectal Neoplasms
12
Stomach Neoplasms
10
Neoplasm Metastasis
10
Esophageal Squamous Cell Carcinoma
9
Advanced Solid Tumor
9
Carcinoma, Hepatocellular
7
Advanced Solid Tumors
5
Squamous Cell Carcinoma of Head and Neck
4
Solid Tumor
4
Melanoma
4
Lung Neoplasms
4
Carcinoma, Transitional Cell
4
Triple Negative Breast Neoplasms
3
Small Cell Lung Carcinoma
3
Recurrence
3
Neoplasms
3
Lymphoma
3
Carcinoma, Renal Cell
3
Breast Neoplasms
3
Uterine Cervical Neoplasms
2
Solid Tumors
2
Sarcoma
2
Neuroendocrine Tumors
2
Lymphoma, T-Cell, Peripheral
2
Lymphoma, Large B-Cell, Diffuse
2
Lymphoma, Extranodal NK-T-Cell
2
Head and Neck Neoplasms
2
Esophageal Neoplasms
2
Colonic Neoplasms
2
Interventions
Gemcitabine
6
Cisplatin
6
pembrolizumab
4
Docetaxel
4
Capecitabine
4
Oxaliplatin
2
Carboplatin
2
toripalimab
1
tocilizumab
1
tislelizumab
1
spartalizumab
1
cc-486
1
Injections
1
Fluorouracil
1
Dexamethasone
1
Azacitidine
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
INDUSTRY
×
Nasopharyngeal Neoplasms
×
tislelizumab
×
Clear all
NCT03924986
2025-01-31
RATIONALE-309
BeiGene
Phase 3
Completed
263 enrolled
19 charts